The collapse has exposed how fragile the “designer baby” business remains, even when it is framed not as enhancement but as disease prevention. Germline editing — altering DNA in embryos in ways that could be inherited by future generations — remains scientifically risky, legally restricted, and ethically explosive. That makes it very different from gene-editing therapies used on living patients, where changes are limited to the treated individual.
The shutdowns also show that venture-backed biotech timelines may be poorly matched to the slow, heavily regulated world of reproductive medicine. Manhattan Genomics reportedly unraveled after governance disputes, while Bootstrap Bio struggled to raise funding and faced additional turmoil after its chief science officer was arrested in 2025. Both companies had launched with ambitions to prevent serious inherited diseases, but neither appears to have reached the kind of scientific, regulatory, or public-trust threshold needed to move the field forward.
Still, the idea is unlikely to disappear. Other companies and investors continue to circle embryo editing and embryo-selection technologies, arguing that they could one day reduce the burden of severe genetic disease. Critics, however, warn that the same tools could slide quickly from prevention into optimization — selecting or editing embryos for traits such as appearance, ability, or intelligence. For now, the failure of Bootstrap Bio and Manhattan Genomics suggests that the industry’s biggest obstacle is not only whether the science can work, but whether society is willing to let it proceed.
